Anxo
瑩碩生技醫藥股份有限公司
Anxo is a Taiwan Emerging Stock Board biotechnology company; its most advanced asset is AX251 (Phase 1; recruiting, Schizophrenia), as of 2026-11-01.
Pipeline
| Asset | Target / mechanism | Stage | Indication | Region | Source date | Source |
|---|---|---|---|---|---|---|
| AX251 | — | Phase 1; recruiting | Schizophrenia | India | 2026-09-16 | Trial registry |
| AX182 | — | — | — | — | — | Company disclosure |
| AX254 | — | — | — | — | — | Company disclosure |
Key events
No verified events in the past twelve months.
Related Drugnews articles
No related articles in this language.